How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers

Qianhui Hua,Hong Xu,Xinyi Chen,Junhang Pan,Ying Peng,Wei Wang,Bin Chen,Jianmin Jiang
DOI: https://doi.org/10.3389/fpubh.2021.736632
IF: 5.2
2021-11-24
Frontiers in Public Health
Abstract:To evaluate China's current rifampin-resistant tuberculosis (RR-TB) screening strategy from stakeholders' perspectives, the perceptions, attitudes, and interests of 245 stakeholders from three eastern, central, and western China provinces on RR-TB screening strategies, were investigated through stakeholder survey and interview. The attitudes toward three RR-TB screening strategies were statistically different: inclination to choose who to screen ( Z = 98.477; P < 0.001), funding for rapid diagnostic technology screening either by reimbursed health insurance or directly subsidized financial assistance ( Z = 4.142, P < 0.001), and respondents' attitude during RR-TB screening implementation levels ( Z = 2.380, P = 0.017). In conclusion, RR-TB screening scope could be expanded by applying rapid diagnostic technologies. Provinces with different economic status could adjust their screening policies accordingly.
public, environmental & occupational health
What problem does this paper attempt to address?